Public expenditure

EAF DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages GrafTech International Ltd. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action – EAF

Retrieved on: 
Sunday, March 24, 2024
Titan, Health, Environment, Class, Public expenditure, Electrode, Particulates, GrafTech, Graphite, Advertising, Sustainable development, Government, Court, EAF

WHAT TO DO NEXT: To join the GrafTech class action, go to https://rosenlegal.com/submit-form/?case_id=22210 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the GrafTech class action, go to https://rosenlegal.com/submit-form/?case_id=22210 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

Levi & Korsinsky Reminds GrafTech International Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2024 – EAF

Retrieved on: 
Thursday, March 21, 2024
Health, Environment, Telephone, LLP, Public expenditure, Electrode, CLASS, Particulates, Graphite, NEXT, COST, Sustainable development, Government, Court, EAF, Cryptocurrency

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GrafTech International Ltd. ("GrafTech" or the "Company") (NYSE: EAF) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GrafTech International Ltd. ("GrafTech" or the "Company") (NYSE: EAF) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GrafTech investors who were adversely affected by alleged securities fraud between February 8, 2019 and August 3, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    EAF investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GrafTech International Ltd. (EAF)

Retrieved on: 
Thursday, March 21, 2024
Health, Environment, GPM, Defendant, News, Public expenditure, Electrode, Particulates, Suite, GrafTech, Graphite, Sustainable development, Government, Court, State, EAF, Cryptocurrency

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • The Company’s International operating license in Mexico was also determined to be no longer in effect.
  • On this news, GrafTech’s stock fell $0.45, or 8.5%, to close at $4.85 on September 19, 2022, thereby injuring investors.
  • Glancy Prongay & Murray LLP, Los Angeles

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

Key Points: 
  • We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
  • Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
  • Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
  • Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

FactSet Reports Results for Second Quarter 2024

Retrieved on: 
Thursday, March 21, 2024
Growth, CFO, EPS, Research, Public expenditure, Table, Eaton Vance, Risk, GAAP, Retirement, Share repurchase, ASV

Buy-side and sell-side organic ASV growth rates for the second quarter of fiscal 2024 were 5.6% and 5.5%, respectively.

Key Points: 
  • Buy-side and sell-side organic ASV growth rates for the second quarter of fiscal 2024 were 5.6% and 5.5%, respectively.
  • Americas revenues for the quarter increased to $352.6 million compared with $331.1 million in the second quarter of last year.
  • FactSet is reaffirming its outlook for fiscal 2024, originally provided on December 19, 2024, but anticipates finishing fiscal 2024 at the lower end of the guidance range for Organic ASV plus professional services growth and GAAP revenues.
  • As previously announced, the Company incurred an approximately $11 million personnel related charge during the second quarter of fiscal 2024 as part of a broader cost optimization program.

EAF INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GrafTech International Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Thursday, March 21, 2024
Health, Environment, Public expenditure, Electrode, Particulates, Complaint, GrafTech, Graphite, Sustainable development, Government, Court, EAF, Person

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GrafTech International Ltd. (“GrafTech” or “the Company”) (NYSE: EAF) and certain of its officers.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GrafTech International Ltd. (“GrafTech” or “the Company”) (NYSE: EAF) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/EAF .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

EAF DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages GrafTech International Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 25 Deadline in Securities Class Action – EAF

Retrieved on: 
Wednesday, March 20, 2024
Titan, Health, Environment, Class, Public expenditure, Electrode, Particulates, GrafTech, Graphite, Advertising, Sustainable development, Government, Court, EAF

WHAT TO DO NEXT: To join the GrafTech class action, go to https://rosenlegal.com/submit-form/?case_id=22210 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the GrafTech class action, go to https://rosenlegal.com/submit-form/?case_id=22210 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

H World Group Limited Reports Fourth Quarter and Full Year of 2023 Unaudited Financial Results

Retrieved on: 
Wednesday, March 20, 2024
PIN, Depreciation, Disclosure, Bank statement, Investment, Marketing, Public expenditure, Income tax, GAAP, Forecasting, Table, Video game

Selling and marketing expenses in the fourth quarter of 2023 were RMB326 million (US$46 million), compared to RMB169 million in the fourth quarter of 2022 and RMB289 million in the previous quarter.

Key Points: 
  • Selling and marketing expenses in the fourth quarter of 2023 were RMB326 million (US$46 million), compared to RMB169 million in the fourth quarter of 2022 and RMB289 million in the previous quarter.
  • General and administrative expenses in the fourth quarter of 2023 were RMB644 million (US$91 million), compared to RMB440 million in the fourth quarter of 2022 and RMB539 million in the previous quarter.
  • Net income attributable to H World Group Limited in the fourth quarter of 2023 was RMB743 million (US$105 million), compared with a net loss attributable to H World Group Limited of RMB124 million in the fourth quarter of 2022 and net income attributable to H World Group Limited of RMB1.3 billion in the previous quarter.
  • Net income attributable to H World Group Limited from the Legacy-Huazhu segment was RMB827 million in the fourth quarter of 2023, compared with a net loss attributable to H World Group Limited from the Legacy-Huazhu segment of RMB84 million in the fourth quarter of 2022 and net income attributable to H World Group Limited from the Legacy-Huazhu segment of RMB1.4 billion in the previous quarter.

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, March 20, 2024
SVB Securities, Epilepsy, Anaphylaxis, Telephone, Patient, Adrenaline, Ageing, Oppenheimer Holdings, Sale, Public expenditure, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.
  • The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million.
  • In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.